
    
      This is a multi-center, two-part study of ION363 in up to 64 participants. Part 1 will
      consist of participants that will be randomized in a 2:1 ratio to receive a multi-dose
      regimen of ION363 or placebo for a period of 29 weeks, followed by Part 2, which will be an
      open-label period where all participants will receive ION363 for a period of 73 weeks.
    
  